Oncogenic mutations in the K-ras gene occur in Ϸ50% of human colorectal cancers. However, the precise role that K-ras oncogenes play in tumor formation is still unclear. To address this issue, we have conditionally expressed an oncogenic K-ras V12 allele in the small intestine of adult mice either alone or in the context of Apc deficiency. We found that expression of K-ras V12 does not affect normal intestinal homeostasis or the immediate phenotypes associated with Apc deficiency. Mechanistically we failed to find activation of the Raf͞MEK͞ERK pathway, which may be a consequence of the up-regulation of a number of negative feedback loops. However, K-ras V12 expression accelerates intestinal tumorigenesis and confers invasive properties after Apc loss over the long term. In renal epithelium, expression of the oncogenic Kras V12 allele in the absence of Apc induces the rapid development of renal carcinoma. These tumors, unlike those of intestinal origin, display activation of the Raf͞MEK͞ERK and Akt signaling pathways. Taken together, these data indicate that normal intestinal and kidney epithelium are resistant to malignant transformation by an endogenous K-ras oncogene. However, activation of K-ras V12 after Apc loss results in increased tumorigenesis with distinct kinetics. Whereas the effect of K-ras oncogenes in the intestine can been observed only after long latencies, they result in rapid carcinogenesis in the kidney epithelium. These data imply a window of opportunity for anti-K-ras therapies after tumor initiation in preventing tumor growth and invasion.
A lthough the molecular genetic events that occur in colorectal cancer have been known for many years, the selective advantage conferred by these mutations has remained unclear (1, 2) . Of these mutations, inactivation of Apc is the most frequent and appears to be the key early event initiating colorectal cancer (3) . Recent in vivo studies using inducible gene deletion have allowed the precise function of Apc in the adult intestine to be defined (4) . These studies have implicated two major functions of Apc in facilitating tumor suppression, namely controlling differentiation and migration.
K-ras is mutated in Ϸ40-50% of colorectal tumors at a relatively early stage of the carcinogenic process and, despite extensive research, the primary reason for this high frequency remains unclear (5) . Ras proteins are prototypic small GTPases that act as molecular switches, transducing signals from the cell surface (from receptor and nonreceptor tyrosine kinases and G protein-coupled receptors) to the nucleus (5) . The most studied downstream effector pathways are the mitogenic Raf-MEK-ERK pathway and the survival phosphatidylinositol 3-kinase pathway. In vitro studies have shown that oncogenic K-ras is required for proliferation, cytoskeleton organisation, adhesion, motility, and invasion of colorectal cancer cells. In these studies, activation of the downstream Raf-MEK-ERK pathways has been demonstrated, and inhibitors to this pathway have been shown to suppress the phenotypes induced by oncogenic K-ras (6) .
To address the role of oncogenic K-ras in vivo, a number of strategies have been used. Most have relied on transgenic overexpression of oncogenic K-ras mutants (7) . A key difficulty in interpreting these studies is that K-ras is normally mutated but not overexpressed in tumors. Thus, overexpression of oncogenic K-ras may yield very different phenotypes to simple mutation. When overexpressed from the villin promoter, mice developed tumors from 8 months of age, although no effects were seen on normal epithelium (7) . As with in vitro studies, activation of Raf-MEK-ERK was observed in both normal and adenomatous tissue. In contrast, expression of oncogenic K-ras from the fatty acid-binding protein promoter only resulted in a proapoptotic phenotype in the context of a simian virus 40 T antigen transgene. In this study, the lack of phenotype mirrored an inability to see up-regulation of Raf-MEK-ERK signaling (8) .
More sophisticated mouse models have been designed in which mutant alleles have been knocked in at the endogenous locus. Moreover, these mutant alleles have been designed so their expression can be controlled in a spatial and temporal manner using tissue-specific Cre and inducible Cre transgenic strains. One of these models involves the expression of an oncogenic K-ras allele under the control of a floxed STOP transcriptional cassette (9, 10) . This oncogenic k-ras allele remains transcriptionally silent until the STOP is removed by a Cre recombinase. These models not only offer the advantage of the controlled expression of the desired knocked-in mutation, but the fact that conditional knockin allele is expressed from its endogenous promoter (9, 10) .
These models have been used to demonstrate that endogenous K-ras oncogenes, activated in different tissues and at different times during embryonic or postnatal development, can induce myeloproliferative disease and carcinomas in various tissues including lung, pancreas, and ovaries (9) (10) (11) (12) . So far, there are no reports for a role of endogenous K-ras oncogenes in intestinal or colon tumors. Apc min mice carrying an oncogenic K-ras allele whose expression required spontaneous recombination failed to display any phenotype significantly distinct of the Apc min strain (9) . Whether these observations were caused by a lack of synergy between the Apc and K-ras mutations or the low percentage of cells expressing the oncogenic K-ras allele could not be determined.
Here, we define the role of an endogenous K-ras oncogene in the adult intestine by using an inducible cre-lox approach. We show that although expression of the oncogenic K-ras allele has little or no effect on intestinal homeostasis or the immediate phenotype after Apc loss the K-ras oncogene does accelerate tumor formation and invasion. Importantly, we also show that expression of an endogenous K-ras oncogene in kidney cells accelerates the formation of renal carcinomas (RCs) after loss of Apc in the renal epithelium.
Results and Discussion
Activation of K-ras Does Not Alter Intestinal Homeostasis. We investigated whether expression of an oncogenic K-ras V12 allele would alter intestinal homeostasis. To this end, we intercrossed K-ras (ϩ/LSLV12) mice bearing a conditional knocked-in K-ras V12 allele whose expression requires Cre-mediated elimination of a STOP transcriptional cassette (10) (Fig. 1A) to mice bearing the cytochrome p450 inducible AhCre transgene (13) . After induction with ␤-naphthoflavone, the AhCre transgene delivers very high penetrance Cre-mediated recombination in both the intestine and liver, with subsequent expression of the oncogenic K-ras V12 allele in these tissues. This targeted allele also carries an IRES-betageo sequence that allows monitoring of successful Cre-mediated recombination through LacZ activity. Therefore, to confirm excision of the STOP cassette, we performed ␤-gal staining on intestinal whole mounts ( Fig. 1 B and C) . Nearly all intestinal cells stained positive for LacZ, indicating successful recombination of the knockin K-ras V12 allele throughout the intestine.
We next characterized the consequences of expressing the oncogenic K-ras V12 allele in the small intestine. Histological analysis revealed no major alterations in the architecture of the crypt-villus axis at 3 days after Cre induction. Crypt size, mitotic index, and levels of apoptosis were scored from these sections and found not to vary significantly between experimental and control tissue at day 3 postinduction (PI). For all comparisons n Ն 3 and Mann-Whitney U P values were Ն0.40 ( Fig. 1 F-H) . Levels of apoptosis were also confirmed independently with immunohistochemistry (IHC) staining for active caspase 3 (14) (data not shown). This failure to observe phenotypic change was consistently observed in mice up to 180 days after Cre induction.
Given previous data suggesting that oncogenic activation of K-ras may alter migration of cells, we determined whether cells expressing the oncogenic K-ras V12 allele were able to migrate normally along the crypt-villus axis. This ''migration'' refers to the upward displacement of intestinal epithelial cells and thus differs from classical cell migration. Mice at day 3 PI were injected with BrdU and killed after 2 or 48 h. Comparison of the distribution of BrdU-positive cells along the axis allows an assessment of the degree of movement along the crypt-villus axis. As shown in Fig. 1I , cells expressing K-ras V12 showed a normal migration pattern between 2 and 48 h postlabeling compared with controls (Kolmogorov-Smirnov test, P ϭ 0.5). The 2-h BrdU labeling experiment described above demonstrated that cells expressing oncogenic K-ras V12 proliferated normally, and that the location and size of the proliferative compartment within the crypt did not differ from controls (P ϭ 0.4, Kolmogorov-Smirnov).
The presence and correct localization of all differentiated intestinal cell lineages was confirmed by use of specific stains or IHC against markers of the differentiated cell types. Alcian blue staining for goblet cells showed that there were similar numbers of goblet cells ( Fig. 1 H-J) ; Grimelius staining showed that there was no significant change in the number of enteroendocrine cells (for all comparisons n Ն 3 and Mann-Whitney U P values were Ն0.39). Antilysozyme staining for paneth cells and antivillin staining for villus enterocytes also revealed no gross change in the number or localization of these cell types (data not shown).
Activation of K-ras Does Not Alter the Levels of Proliferation or
Apoptosis After Apc Loss. In colorectal cancer, K-ras mutations occur after Apc mutations, so we next examined whether Cremediated expression of oncogenic K-ras V12 affected the immediate phenotypes of Apc deficiency. This was achieved by intercrossing AhCre ϩ/T , K-ras ϩ/LSLV12 animals with Apc fl/fl mice bearing a loxP flanked Apc 580 allele (15) . The resulting AhCre ϩ/T , K-ras ϩ/LSLV12 , Apc fl/fl mice were then induced with ␤-naphthoflavone.
Histological analysis revealed that K-ras V12 expression had little impact on the previously reported phenotypes of Apc deficiency (4) (Fig. 4 B and C, which is published as supporting information on the PNAS web site). Crypt size, mitotic index, and levels of apoptosis all were increased compared with WT mice but were indistinguishable to that of Apc-deficient mice (for all comparisons n Ն 3 and Mann-Whitney U P values were Ն0.40) (Fig. 4 D-F) . IHC for BrdU and Ki67 showed K-ras V12 expression did not increase levels of cell turnover, with proliferation independent of position in both genotypes. Likewise, K-ras V12 expression did not significantly alter the number of enteroendocrine cells, the mislocalization of paneth cells, or the reduction in villin expression after Apc loss (data not shown). However, there was significant rescue in the number of goblet cells after Apc loss [34 Ϯ 14 (Apc fl/fl ) vs. 113 Ϯ 10 (K-ras (ϩ/LSLV12) , Apc fl/fl ), P ϭ 0.04 Mann-Whitney, n ϭ 3] (Fig.  4 I-J) . Taken together, these data suggest that Apc loss alone is sufficient to induce the vast majority of changes that occur at the earliest stages of neoplasia and that K-ras V12 expression at these stages confers little, if any, additional phenotype.
Raf-MEK-ERK and Wnt Signaling Pathways Are Not Dysregulated After
Expression of Oncogenic K-ras V12 . Given our failure to observe any phenotypic change after expression of the oncogenic K-ras V12 allele, we next investigated whether the Raf-MEK-ERK pathway was activated. IHC for P-MEK and P-ERK indicated that these phospho-proteins are normally present in the cytoplasm of intestinal enterocytes and that expression of oncogenic K-ras V12 , either alone or in the context of Apc deficiency, did not affect either the levels or the localization of these proteins (Fig. 5a A-I , which is published as supporting information on the PNAS web site). These observations provide a molecular explanation for our failure to see phenotypic changes after activation of K-ras V12 expression. These data also argue against the notion that Apc inhibits activation of the Raf-MEK-ERK pathway in vivo, as recently suggested (16) . Interestingly, nuclear P-MEK and P-ERK were observed in goblet cell nuclei, suggesting that this pathway may be relevant to goblet cell differentiation (Fig. 5aF) . This may also explain the partial rescue of goblet cell loss, which we report in Apc-deficient cells that express the oncogenic K-ras V12 allele.
We next investigated expression of cell-cycle proteins cyclin D1 and p21, which have also been reported to become up-regulated after expression of K-ras oncogenes (12) . However, IHC showed no changes of localization or expression of either p21 or cyclin D1 after K-ras activation (data not shown). Previous studies have suggested that oncogenic K-ras may also activate Wnt signaling (17) . Within the intestinal crypt, levels of Wnt signaling are crucial for the establishment of cell positioning, differentiation, and proliferation (4). We therefore examined expression of ␤-catenin after Cremediated expression of the oncogenic K-ras V12 allele in otherwise normal epithelium. No changes were observed in either the level or location of ␤-catenin in cells expressing oncogenic K-ras V12 as determined by IHC (Fig. 5a K-L) . These data, in conjunction with the failure to see changes in crypt kinetics or up-regulation of the Wnt targets CD44 and C-Myc (WT vs. K-ras (ϩ/LSLV12) , 1.31-and 0.83-fold by quantitative RT-PCR (qRT-PCR), respectively, MannWhitney P Ͼ 0.4), argue that Wnt signaling was unaltered despite oncogenic K-ras V12 expression.
We also determined whether expression of the K-ras V12 allele altered Wnt signaling after Apc gene deletion. Irrespective of K-ras V12 expression status, ␤-catenin translocated to the nucleus (Fig. 5a M and N 
Up-Regulation of Negative Regulators of Raf-MEK-ERK Signaling.
Previously we have shown that numerous negative feedback loops are activated after Apc loss in vivo (4) . Thus, we observe upregulation of Axin-2, Wisp1, Wif-1, and Frizzled 6 after Apc loss. However, in the absence of Apc, these proteins are unable to prevent dysregulated Wnt signaling (2) (Fig. 5aM) . A different scenario exists after expression of the oncogenic K-ras V12 allele, as a number of studies have indicated that activation of the Ras signaling pathway can be attenuated through reducing the phosphorylation status of the downstream proteins Raf-MEK-ERK (18) . Importantly, this has been the rationale behind developing kinase inhibitors to Raf and a number of other downstream effectors of Ras signaling.
To further explore the molecular consequences of oncogenic K-ras V12 expression, we performed microarray experiments using MOE4302 chips comparing control and AhCre ϩ , K-ras
intestines. Using significance analysis of microarray analysis and a false discovery rate of 5% we identified a small number of changes specific to K-ras V12 expression. Of these, a number have previously been associated with Ras or G protein receptor signaling (Table 1 , which is published as supporting information on the PNAS web site). Regulator of G protein signaling-5 (RGS5), a potential negative regulator of Ras signaling, was up-regulated in the array and confirmed by qRT-PCR to be 3-fold elevated after Cremediated induction of K-ras V12 expression. This protein was originally identified in a screen for regulators of G protein signaling and has been shown to attenuate ERK activation in vivo (19, 20) .
The most studied phosphatases of the Raf-MEK-ERK pathway are the Dusp͞MKP phosphatases. Our previous microarray analysis of Apc-deficient intestines had suggested that Dusp4͞Mkp2 and Dusp9͞Mkp4 were both up-regulated after Apc loss. To investigate this we performed IHC against Dusp4 after Apc loss and confirmed Dusp4 to be up-regulated immediately after Apc loss and to be independent of K-ras status (Fig. 6 , which is published as supporting information on the PNAS web site). We also used qRT-PCR to confirm 5-fold up-regulation of Dusp9 after Apc loss, which again was independent of K-ras V12 expression. Previous studies have shown that K-ras-mediated transformation of pancreatic cells in vitro can be suppressed by cotransfection with vectors containing Dusp4 (21) . Deregulation of Dusp4 and Dusp9 therefore provides a ready mechanism to explain the lack of additional phenotype we see after K-ras V12 expression.
Expression of K-ras V12 Accelerates Tumorigenesis and Causes Invasion
After Apc Loss. After establishing that K-ras V12 expression has no detectable impact on the immediate consequences of Apc loss, we next investigated whether expression of this oncogenic allele could accelerate the appearance of adenomas. Cohorts of (AhCre ϩ/T ,
ϩ/fl ), and (AhCre ϩ/T , K-ras ϩ/LSLV12 , Apc ϩ/fl ) mice were induced with ␤-naphthoflavone at weaning (3 ϫ 80 mg͞kg ␤-naphthoflavone i.p.). This protocol effectively renders the animals either WT or constitutively heterozygous for Apc from weaning, and additionally either WT or activated for K-ras. Cohorts were aged until they developed symptoms of intestinal neoplasia (anaemia, pale feet, hunching, and swollen abdomen). Fig. 2 A and B shows an intestinal whole mount of an AhCre ϩ/T , K-ras ϩ/LSLV12 , Apc ϩ/fl mouse at 150 days after induction of Cre expression stained for ␤-gal activity. LacZ staining was observed in both normal and adenomatous tissue throughout the intestine, consistent with high levels of Cre-induced expression of the conditional K-ras V12 allele. All adenomas were characterized by nuclear ␤-catenin, strongly implicating loss of the remaining Apc allele (Fig. 2 D and E) . Fig. 2C shows that expression of K-ras V12 rapidly accelerated intestinal tumorigenesis after Apc loss. By 165 days, 17 of 21 (81%) AhCre ϩ/T , K-ras ϩ/LSLV12 , Apc ϩ/fl animals had become symptomatic of disease and were culled because of the development of multiple intestinal tumors. Instead, only 2 of 20 (10%) AhCre ϩ/T , K-ras ϩ/ϩ , Apc ϩ/fl mice had a similar phenotype ( 2 ϭ 20.739, df ϭ 1, P ϭ 0.0001). At death, there was no significant difference in tumor number or size (Mann-Whitney P Ͼ0.4, n ϭ 18 and n ϭ 6), indicating that mice were being culled when they had a similar tumor burden.
As K-ras oncogenes had previously been associated with increased mobility of colorectal cancer cells in vitro (6), we investigated whether the invasive status of the tumors was altered in AhCre ϩ/T , K-ras ϩ/LSLV12 , Apc ϩ/fl mice. No adenocarcinomas were found in 100 tumors analyzed in AhCre ϩ/T , K-ras ϩ/ϩ , Apc ϩ/fl mice. These data consolidate data in the Apc ϩ/Min mouse, which rarely, if ever, show progression to adenocarcinoma and do not show K-ras mutations. However 17 of 100 tumors arising in AhCre ϩ/T , K-ras ϩ/LSLV12 , Apc ϩ/fl double mutant mice showed morphological evidence of invasion into the smooth muscle and were classified as adenocarcinomas (Fig. 2 F-I ). This significant increase in invasion ( 2 ϭ 18.579, df ϭ 1, P ϭ 0.001) was observed despite the early onset of tumor formation in this cohort.
We next investigated whether this increased tumorigenesis was associated with activation of the Raf-MEK-ERK pathway. Previous studies in vivo in both the colon and lung had failed to see dysregulation of these pathways after K-ras oncogene expression, even within tumors (9, 12) . Although we did not see gross activation of Raf-MEK-ERK signaling in all intestinal adenomas, we did observe higher levels of P-MEK and occasional nuclei positive for P-ERK in a proportion of the small intestinal adenomas (Ϸ10%) arising in AhCre ϩ/T , K-ras ϩ/LSLV12 , Apc ϩ/fl mice. Similar changes were not observed in the AhCre ϩ/T , K-ras ϩ/ϩ , Apc ϩ/fl cohort. There was also no gross activation of the Akt signaling pathways with similar patterns and levels of expression of P-Akt Ser-473 and its downstream effectors mTor Ser-2448 and S6 kinase Thr-421,Ser-424 (data not shown). These data suggest either that relatively low-level activation of the Raf-MEK-ERK pathway is sufficient to mediate the effects of the K-ras V12 oncogene or that alternate pathways are responsible.
The K-ras V12 Oncogene Accelerates RC with Concomitant Activation of Raf-MEK-ERK and Akt Signaling Pathways. The AhCre transgene also drives constitutive expression of Cre recombinase in the renal epithelium without causing Apc loss in the intestine. This property has been used to drive homozygous deletion of Apc in AhCre ϩ , Apc fl/fl animals. Indeed, these mice spontaneously develop RC with an incidence of 30% at 12 months at age. These tumors invariably display loss of both Apc alleles. The relative low frequency of tumors, despite high levels of Cre-mediated recombination, appears to reflect spontaneous deletion of the majority of Apc-deficient cells in a p53-dependent manner (22) .
To investigate whether expression of the K-ras V12 oncogene accelerates RC in these mice, we first examined kidneys from (AhCre (Fig. 3A) . To further analyze the onset of RC we then aged cohorts of (AhCre ϩ/T , K-ras ϩ/ϩ , Apc fl/fl ) and (AhCre ϩ/T , K-ras ϩ/LSLV12 , Apc fl/fl ) mice (n ϭ 10) until they became symptomatic of disease (swollen, blood in urine, anemic). By 4 months of age all double mutant AhCre ϩ/T , K-ras ϩ/LSLV12 , Apc fl/fl animals became ill and were confirmed to have RC (Fig. 3 B and  C) . At this time point, no RC was observed in the AhCre ϩ/T , K-ras ϩ/ϩ , Apc fl/fl cohort. Molecular analysis revealed nuclear ␤-catenin within every kidney lesion, implying loss of the WT Apc alleles (Fig. 3 D and E) . P21 and cyclin D1 was also up-regulated within most lesions (Fig. 3L and data not shown) . Critically, we observed up-regulation of P-MEK and nuclear P-ERK, indicating that the Raf-MEK-ERK pathway was activated within these tumors (Fig. 3  F-I) . We also observed up-regulation of P-Akt Ser-473 and the downstream effectors mTOR 2448 and S6 kinase Ser-421/Thr-424 ( Fig. 3  J and K) . Up-regulation of Akt signaling and particularly mTOR has previously be associated in RC because of loss of the tuberous sclerosis tumor suppressor genes (TSC1 or TSC2) (23) .
The relative lack of lesions in the AhCre ϩ/T , K-ras ϩ/ϩ , Apc fl/fl mice at these stages suggests that expression of the oncogenic K-ras V12 allele allows the survival of Apc-deficient cells during the early stages of tumorigenesis. This parallels our previous study where we found p53 deficiency also accelerated tumorigenesis, although this effect was less marked than that observed here. K-ras V12 expression is also likely to drive increased lesion growth, as Apc-deficient kidneys are characterized by ␤-catenin-positive foci at 3 months but these do not progress to RC until many months later (22) .
Two previous studies have shown activation of the Raf-MEK-ERK pathways in tumors in vivo after endogenous K-ras oncogene activation. Notably, one of these studies required coincident loss of PTEN in endometrioid ovarian adenocarcinoma (24) . The second study was performed in pancreatic adenocarcinomas after combined expression of an oncogenic K-ras allele and loss of p53 (25) . Together with the data presented here, these studies argue that both cellular and genetic contexts are critical determinants of the consequences of K-ras mutation. The observed differences in renal, pancreatic, and intestinal epithelium may reflect the relatively high levels of P-MEK and P-ERK staining in normal intestinal enterocytes compared with normal renal or pancreatic epithelium. Thus, the effects of K-ras mutation may be less aggressive in tissues (such as the intestinal epithelium) in which these pathways are normally activated and where the appropriate feedback loops are expressed. In this light it is of interest to note that within Madin Darby canine kidney cells loss of active ERK͞MEK signaling restores cells to an epithelial state (26) .
In the intestine, oncogenic K-ras expression leads to both accelerated adenoma development and increased invasiveness, but only after Apc deficiency. The latter effect is of particular note as one of the immediate phenotypes of Apc deficiency is a complete loss of cell migration and coincident up-regulation of proteins such as TIAM1 (27) and the EphB receptors (28) . The later stages of colorectal cancer are marked by a progressive deregulation of proteins, including E-Cadherin, and the EphB receptors, which may reverse this consequence of Apc loss and so permit invasion. Our data suggest that expression of oncogenic K-ras provides a further mechanism for this reversal (28) .
In summary, we have elucidated the consequences of expressing an endogenous K-ras V12 oncogene in intestinal and renal epithelium. Expression of the K-ras V12 oncogene in these tissues by itself had no phenotypic consequences. However, Apc deficiency makes these cells permissive for the tumorigenic properties of K-ras oncogenes. These tissues, however, differ markedly in the specific contributions of K-ras V12 expression. Whereas the renal epithelium is exquisitely sensitive to the consequences of K-ras V12 expression in the absence of Apc, expression of oncogenic K-ras V12 in the intestinal epithelium has little or no impact on physiology and does not accentuate the immediate effects of Apc deficiency. However, over the long term, oncogenic K-ras V12 expression accelerates both intestinal adenoma formation and invasion. These data demonstrate distinct tissue-specific responses to K-ras oncogenes, differences that may reflect the activation state of the Raf-MEK-ERK pathway in these tissues.
Materials and Methods
Experimental Animals. All procedures were conducted according to U.K. Home Office regulations. Mice were maintained on an outbred background, and all mice were genotyped as described for the targeted Apc 580s allele (15), K-ras V12 allele (10) , and the AhCre transgene (13) . Cre activity was induced in control and experimental mice by 3 i.p. injections of 80 mg͞kg ␤-naphthoflavone within 24 h (4, 13).
Assaying Crypt Size, Apoptosis, Mitosis, and S-Phase Labeling in Vivo.
Apoptosis, crypt size, and mitotic index were scored from H&E-stained sections as described (4) . For each analysis, 25 full crypts were scored from at least three mice of each genotype. For BrdU labeling, mice were injected either 2 h or 48 h before culling with 0.25 ml of BrdU (Amersham, Piscataway, NJ), and staining was performed using an anti-BrdU antibody (BD, Franklin Lakes, NJ) at 1 part in 100. At least three mice were used for each genotype and time point ␤-Gal Analysis. Intestinal whole mounts were prepared, fixed, and exposed to X-Gal substrate by using a method as reported (4).
Histology and IHC.
Intestinal tissue was fixed in ice-cold 10% neutral buffered formalin for no longer than 24 h before being processed into paraffin blocks according to standard procedures. Tissue sections (5 m) were either stained with H&E for histological analysis or used for IHC. The details of the antibodies used are given in Supporting Text, which is published as supporting information on the PNAS web site.
RNA Extraction and Affymetrix Microarray Analysis. Eight-week-old male mice were used for the array analysis. Three centimeters of the small intestine located 7 cm from the stomach was placed in RNAlater (Ambion, Austin, TX) (after removing any mesentery and ensuring that no Peyer's patches were present). The tissue was then homogenized in Trizol reagent, and RNA was extracted by using standard phenol-chloroform methodologies. Biotinylated target cRNA was generated as described (4) . Affymetrix (Santa Clara, CA) gene arrays were run at the Cancer Research U.K. facility at the Paterson Institute for Cancer Research. Samples were hybridized to MOE4302 chips. In total, six chips were used: three for WT intestine and three for K-ras v12 intestine (each chip represented RNA made from an individual mouse intestine). Raw signal intensities were initially screened by using the MaxD͞View program to remove false-positive and false-negative signals (using a cutoff of at least one P value for each transcript Ͻ 0.2). The data were then normalized by global normalization, using the MaxD͞ View-Program (4). qRT-PCR was performed as described in Supporting Text. 
